73 results
Page 2 of 4
8-K
EX-99.1
wr7wk54 i8zcu67p
15 Nov 21
Regulation FD Disclosure
7:57am
424B5
0iyv9 0uhxkgmh0f83f
1 Oct 21
Prospectus supplement for primary offering
5:10pm
POS AM
qtvoq5fucg
21 May 21
Prospectus update (post-effective amendment)
4:10pm
8-K
EX-99.1
ly6ehq4dsd6puc
18 Mar 21
Regulation FD Disclosure
8:00am
POS AM
lnba d3b8etkn
9 Mar 21
Prospectus update (post-effective amendment)
4:56pm
POSASR
ipcp0crl2bdn 42pqzx6
9 Mar 21
Automatic shelf registration (post-effective amendment)
4:04pm
424B5
92nh2de 2n
22 Jun 20
Prospectus supplement for primary offering
5:22pm
S-3ASR
r18i4lfg4 yxm
22 Jun 20
Automatic shelf registration
4:52pm
8-K
EX-99
3q67905rcaotp pwx4
5 Jun 20
Regulation FD Disclosure
4:05pm
8-K
EX-99
bzrp2e4x90vq610
19 May 20
Cue Biopharma Reports First Quarter 2020 Results, Updates ofCUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
4:06pm